<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01319240</url>
  </required_header>
  <id_info>
    <org_study_id>NN9068-3871</org_study_id>
    <secondary_id>2010-021190-36</secondary_id>
    <secondary_id>U1111-1119-2417</secondary_id>
    <nct_id>NCT01319240</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of Insulin Degludec/Liraglutide (A3) in Healthy Subjects</brief_title>
  <official_title>A Trial to Investigate Pharmacokinetics, Safety and Tolerability of Insulin Degludec/Liraglutide (A3) Compared With Insulin Degludec and Liraglutide in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this trial is to compare the bioavailability of&#xD;
      insulin degludec and liraglutide, when administered either combined or as separate&#xD;
      administrations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The area under insulin degludec concentration-time curve</measure>
    <time_frame>from 0-infinity hours after trial product administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The area under liraglutide concentration-time curve</measure>
    <time_frame>from 0-infinity hours after trial product administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The area under insulin degludec concentration-time curve</measure>
    <time_frame>from 0-120 hours after trial product administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The area under liraglutide concentration-time curve</measure>
    <time_frame>from 0-72 hours after trial product administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration of insulin degludec</measure>
    <time_frame>from 0-120 hours after trial product administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration of liraglutide</measure>
    <time_frame>from 0-72 hours after trial product administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hypoglycaemic episodes</measure>
    <time_frame>From day 0 to 7-14 days after 3rd trial product administration</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Diabetes</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>IDegLira</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IDeg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lira</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin degludec</intervention_name>
    <description>Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.</description>
    <arm_group_label>IDeg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin degludec/liraglutide</intervention_name>
    <description>Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.</description>
    <arm_group_label>IDegLira</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.</description>
    <arm_group_label>Lira</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent obtained before any trial-related activities. (Trial-related&#xD;
             activities are any procedure that would not have been performed during normal&#xD;
             management of the subject)&#xD;
&#xD;
          -  Body Mass Index (BMI) between 20.0 and 27.0 kg/m^2 (both inclusive)&#xD;
&#xD;
          -  Body weight between 75 kg and 90 kg (both inclusive)&#xD;
&#xD;
          -  Fasting plasma glucose below 6.1 mmol/L (110 mg/dL)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected hypersensitivity to trial products or related products&#xD;
&#xD;
          -  Previous participation in this trial. Participation is defined as randomised&#xD;
&#xD;
          -  Previous participation in any other clinical trial involving other investigational&#xD;
             products within the last 3 months before dosing in this trial&#xD;
&#xD;
          -  Donation of any blood or plasma in the past month or in excess of 500 mL within the 3&#xD;
             month preceding screening (trial start) or surgery or trauma with more than 500 mL&#xD;
             blood loss within the 3 month preceding screening&#xD;
&#xD;
          -  History of or presence of cancer, or any clinically significant cardiovascular,&#xD;
             respiratory,metabolic, renal, hepatic, gastrointestinal, endocrine, diabetes,&#xD;
             haematological, dermatological,venereal, neurological, psychiatric diseases or other&#xD;
             major disorders that might have impact on the trial, as judged by the Investigator&#xD;
             (Trial Physician)&#xD;
&#xD;
          -  Clinically significant abnormal haematology, biochemistry, lipids, urinalysis or&#xD;
             coagulation screening tests, as judged by the Investigator (Trial Physician)&#xD;
&#xD;
          -  Known hepatitis or known carrier of the hepatitis B surface antigen (HBsAg) or&#xD;
             hepatitis C antibodies, or a positive result to the test for HIV (human&#xD;
             immunodeficiency virus) antibodies and antigen&#xD;
&#xD;
          -  Family or personal history of MEN2 (Multiple endocrine neoplasia syndrome type 2) or&#xD;
             familial medullary thyroid carcinoma (FMTC)&#xD;
&#xD;
          -  History of chronic pancreatitis or idiopathic acute pancreatitis&#xD;
&#xD;
          -  Supine blood pressure at screening, after resting for 5 min, outside the range of&#xD;
             90-140 mmHg systolic or 50-90 mmHg diastolic (excluding white-coat hypertension;&#xD;
             therefore, if a repeated measurement on a second screening visit shows values within&#xD;
             the range, the subject can be included in the trial) or resting heart rate outside the&#xD;
             range of 40-90 bpm&#xD;
&#xD;
          -  Clinically significant abnormal ECG (Electrocardiogram) at screening (trial start)&#xD;
&#xD;
          -  Significant history of alcoholism or drug/chemical abuse, or a positive result of the&#xD;
             urine drug screen or alcohol breath test, or consuming more than 21 units of alcohol&#xD;
             per week (one unit of alcohol equals about 250 mL of beer or lager, one glass of wine,&#xD;
             or 20 mL spirits)&#xD;
&#xD;
          -  Smoking more than 5 cigarettes, or the equivalent, per day and unable to refrain from&#xD;
             smoking during the in-house periods&#xD;
&#xD;
          -  Mental incapacity or language barriers which preclude adequate understanding or&#xD;
             cooperation,unwillingness to participate in the trial or subjects that in the opinion&#xD;
             of Investigator (trial physician) should not participate in the trial&#xD;
&#xD;
          -  Use of any prescription or non-prescription medication, except for paracetamol,&#xD;
             acetylsalicylic acid, and vitamins (but including mega-dose vitamin therapy, as judged&#xD;
             by the Investigator (trial physician)) within 2 weeks before the trial&#xD;
&#xD;
          -  Any condition that would interfere with trial participation or evaluation of results,&#xD;
             as judged by the Investigator (trial physician)&#xD;
&#xD;
          -  Subjects with a history of deep leg vein thrombosis or with frequent appearance of&#xD;
             deep leg vein thrombosis in 1st degree relatives as judged by the Investigator (trial&#xD;
             physician)&#xD;
&#xD;
          -  Males who are sexually active and not surgically sterilised, who or whose partner are&#xD;
             not using adequate contraceptive methods (adequate contraceptive measures as required&#xD;
             by local law or practice)&#xD;
&#xD;
          -  Baseline (screening) calcitonin level above or equal to 50 ng/L&#xD;
&#xD;
          -  Suffer from a life threatening disease&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>March 18, 2011</study_first_submitted>
  <study_first_submitted_qc>March 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2011</study_first_posted>
  <last_update_submitted>October 1, 2015</last_update_submitted>
  <last_update_submitted_qc>October 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Xultophy</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

